In Vivo Expression of Recombinant Pregnancy-Specific Glycoprotein 1a Inhibits the Symptoms of Collagen-Induced Arthritis

FALCÓN CRISTIAN ROBERTO; MARTINEZ FERNANDO; CARRANZA FRANCO; CERVI LAURA; MOTRÁN CRISTINA

AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY

WILEY-BLACKWELL PUBLISHING, INC

Lugar: Londres; Año: 2014 vol. 72 p. 527 - 533

1046-7408

ProblemThe contribution of Pregnancy-specific glycoproteins (PSG), the majorvariant of PSG released into the circulation during pregnancy, to thepregnancy-dependent improvement of rheumatoid arthritis (RA) hasstill not been elucidated.Method of studyCollagen-induced arthritis (CIA) was used to test the hypothesis thatPSG1a when released into circulation has a modulatory role on theTh1-pathogenic response, thus improving the CIA symptoms. In vivoexpression of PSG1a was induced by injection of the vaccinia (Vac)-based expression vector harboring the complete open-reading frame ofPSG1a cDNA.ResultsIn vivo PSG1a expression during the induction of CIA ameliorated theclinical symptoms, thereby reducing the arthritis score and incidence.Significantly lower levels of IL-17, IL-6, and IFN-c, but higher levels ofTGF-b and IL-10 were secreted by collagen type II-stimulated spleenmononuclear cells from Vac-PSG1a-treated mice compared with controlmice. Moreover, Vac-PSG1a treatment promoted the increase in splenicCD4+CD25+Foxp3+ Treg cells.ConclusionPre-clinical Vac-PSG1a treatment suppressed the Th1- and Th17-type-specificresponses, leading to an increase in splenic Treg cells as well as IL-10- and TGF-b-secreting cells, with the CIA symptoms being ameliorated